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Summary Oxaliplatin, a new third-generation platinum complex, is active in the treatment of colorectal and advanced ovarian cancers, both
as monotherapy and in combination therapy. It has demonstrated a very good safety profile, characterized by low haematotoxicity, and
moderate and manageable gastrointestinal toxicity. No significant renal or ototoxicities have been observed. Oxaliplatin induces a peripheral
sensory neuropathy which is characterized by distal and perioral dysaesthesia, and is induced or exacerbated by the cold; in general, it is
regressive between cycles of treatment. This dose-limiting toxicity is cumulative, but reversible within a few months of discontinuation of
treatment in the majority of cases. In a cohort study of 490 patients with advanced colorectal cancer included in an extended access
programme, more than 2700 cycles of oxaliplatin plus 5-fluorouracil (5-FU) were administered. The overall safety profile of oxaliplatin was
shown to be very favourable. Oxaliplatin and cisplatin, each in combination with cyclophosphamide, have a similar efficacy in the treatment of
advanced ovarian cancer, but oxaliplatin was better tolerated than cisplatin in terms of haematological, gastrointestinal, neurosensory and
renal toxicities. The safety profile of oxaliplatin makes it an ideal candidate for combination therapy.
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Oxaliplatin was introduced into clinical trials by Mathe and
colleagues in 1986, and has been approved in France for the treat-
ment of advanced colorectal cancer, both as monotherapy and in
combination with 5-fluorouracil (5-FU)/folinic acid (FA), for more
than a year. To date, more than 2000 patients have received oxali-
platin in clinical trials, 1400 ofthese for the treatment ofmetastatic
colorectal cancer. All of these studies have confirmed the efficacy
and favourable toxicity and safety profiles ofoxaliplatin.
Oxaliplatin as monotherapy has also shown activity in
pretreated ovarian cancer patients (Misset et al, 1991). The lack of
cross-resistance with cisplatin and carboplatin has been demon-
strated in human ovarian cancer cell lines, both in vitro and in vivo
(Pendyala et al, 1993; Alvarez et al, 1994). This activity profile,
together with an excellent tolerability, provides the rationale for
the use of oxaliplatin in combination with cisplatin in pretreated
ovarian cancer patients. The combinations ofoxaliplatin-cisplatin
and oxaliplatin-cisplatin-epirubicin-ifosmamide have been
shown to be active in such patients (Soulie et al, 1996, 1997).
Oxaliplatin is a non-conventional platinum compound that
differs from cisplatin in its lack ofnephrotoxicity and from carbo-
platin in its association with only limited haematological toxicity.
The most frequent acute side-effect of oxaliplatin is a transient
peripheral neuropathy, manifesting as parasethesia and dysaes-
thesia in the extremities, which is triggered or enhanced by
exposure to cold. These are discussed below.
TOXICITY PROFILE
Haematotoxicity
In a large phase I study, 44 patients with advanced cancer received
116 courses of oxaliplatin, with dose escalation from 45 to
200 mg m-2 (Extra et al, 1990). Most patients had previously
received chemotherapy. Moderate haematological toxicity was
observed. Thrombocytopenia was dose related and did not occur at
doses of oxaliplatin less than 90 mg m-2; however, it did occur in
13% ofpatients receiving doses of 135-150 mg m-2, and 28.5% of
those treated with 175-200 mg m-2 exhibited a decreased platelet
count that did not exceed World Health Organization (WHO)
grade 2. Similarly, only grade 1 or 2 neutropenia was observed,
and haemoglobulin levels generally remained unchanged.
Table 1 summarizes the incidence ofgrade 3 and 4 haematotox-
icity as a result ofthe administration ofoxaliplatin in combination
with 5-FU/FA (Levi et al, 1992; de Gramont et al, 1997). The 39%
grade 3 and 4 neutropenia observed in the Folfox 2 study was
manageable, and was a result of5-FU. It could be avoided in most
patients as it almost always occurred after 5-FU dose escalation,
and did not recur after further dose adjustment. No haematopoietic
growth factors were used.
Thus, oxaliplatin in combination with 5-FU/FA does not
increase the haematological toxicity. Indeed, the profile resulting
from this treatment combination is almost entirely the result ofthe
5-FU/FA component ofthe treatment.
Renal toxicity
Unlike cisplatin, oxaliplatin does not appear to be nephrotoxic, and
its administration does not require any specific nephroprotective
measures (e.g. hyperhydration). The pharmacokinetic behaviour of
oxaliplatin has been evaluated inpatients with normal and impaired
kidney function (creatinine clearance value, < 60 ml min-')
(Massari et al, 1994; Raymond et al, 1998). Results showed that,
after a 2-h infusion of oxaliplatin, no differences were observed
between the plasma concentration ofthe drug in patients with renal
impairment and in those with normal renal function, suggesting that
dose modification was not required in patients with impaired renal
function. Forty-nine patients with impaired renal function have
been treated with full-dose oxaliplatin, either as monotherapy or
in combination, without evidence of increased nephrotoxicity
(Massari et al, 1996).
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Table 1 Comparative haematological toxicity (WHO grades 3 and 4) of
oxaliplatin (L-OHP) and oxaliplatin combined with 5-fluorouracil (5-FU) and
folinic acid (FA)
L-OHP L-OHP + 5-FU/FA
Folfox 2 CM
Number of patients 124 46 93
Anaemia (%) 3 0 <1
Thrombocytopenia (%) 2 11 0
Neutropenia (%) 1 39 3
CM, chronomodulation.
Gastrointestinal toxicity
Nausea and/or vomiting were observed in the majority ofpatients,
and it did not seem to increase with the addition of5-FU (Table 2).
Severe nausea and vomiting were seen in 10% ofpatients treated
with oxaliplatin as monotherapy and in 22% of those treated with
oxaliplatin in combination with 5-FU. These symptoms can
usually be controlled with supportive measures, including anti-
5HT3 medications and loperamide. Diarrhoea appears to be more
frequent and severe with longer infusion schedules. Severe diar-
rhoea occurs in approximately 4% of patients who have received
oxaliplatin monotherapy compared with 25.3% of patients who
have received oxaliplatin plus 5-FU. The incidence of severe
mucositis is dependent on the 5-FU regimen used in the studies.
Neurotoxicity
Acute neurotoxicity associated with oxaliplatin is common
(85-95% of patients) but usually not dose-limiting, occurring
within hours of treatment and regressing between treatments.
Typical symptoms have included paraesthesias, usually presenting
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Figure 1 The cumulative incidence rate of grade 3 (specific scale)
neuropathy in 682 patients receiving oxaliplatin as monotherapy or in
combination therapy
as cold-related dysaesthesias, which were seldom painful or asso-
ciated with cramps. The majority of these toxicities lasted for
7 days or less, and resolved between treatments. A sporadic, some-
times sudden, and self-limiting laryngopharyngeal dysaesthesia is
thought to result from decreased sensitivity of the larynx and
pharynx, which causes a feeling ofdifficulty in breathing or swal-
lowing. Symptoms have resolved spontaneously within hours of
onset. Symptoms tended to last longer with successive cycles.
Neurological toxicity scales currently available are generally
insufficient for grading the characteristics of the dysaesthesia
associated with oxaliplatin use. Consequently, a grading system
was developed by Levi and co-workers that takes into account
both intensity and duration of symptoms related to oxaliplatin-
induced paraesthesia/dysaesthesia (Caussanel et al, 1990). This is
shown in Table 3, in which it is compared with the WHO grading
system for neurotoxicity.
Table 2 Gastrointestinal toxicity found with oxaliplatin as monotherapy and in combination with 5-FU/FA (Massari et al, 1996)
Oxaliplatin monotherapy Oxaliplatin plus 5-FU/FA
Number of All grades of Grades Number of All grades of Grades
patients toxicity (%) 3/4 (%) patients toxicity (%) 3/4 (%)
Nausea/vomiting 262 64.9 10.7 381 89.8 22.3
Diarrhoea 250 30.4 4 376 84.8 25.3
Table 3 The specific grading system of Levi for neurosensory toxicity compared with the WHO system for grading neurotoxicity (Levi et al, 1992)
WHO Specific scale (after Levi)
0 Nothing 0 Nothing
1 Paraesthesias and/or reduction of 1 Paraesthesias and/or dysaesthesias
tendinous reflex (induced by cold) with complete
regression within 1 week
2 Severe paraesthesias and/or moderate 2 Paraesthesias and/or dysaesthesias with
asthenia complete regression within 21 days
3 Intolerable paraesthesias and/or 3 Paraesthesias and/or dysaesthesias with
reduction of muscular force incomplete regression at day 21
4 Paralysis 4 Paraesthesias and/ordysaesthesias with
functional consequence
British Journal ofCancer (1998) 77(Supplement 4), 4-7 0 CancerResearch Campaign 19986 J-L Misset
Table 4 Percentage of patients whose neurotoxicity reversed after
discontinuation of oxaliplatin treatment
Neurotoxicity Time after treatment discontinuation
1 month 3 months 6 months 9 months 12 months
Total 1 6 18 28 41
disappearance (%)
Total and partial 6 38 65 76 82
disappearance (%)
No change (%) 91 62 35 22 18
Table 5 Overall toxicity seen in patients treated with oxaliplatin in
combination with 5-FU/FA (number of patients, 472; number of cycles, 2645)
(data on file)
Percentage of patients with
grade 3/4 toxicity (% cycles)
Haematological toxicity
Anaemia
Leucopenia
Neutropenia
Thrombocytopenia
Gastrointestinal
Nausea/vomiting
Diarrhoea
Mucositis
Neurotoxicity (specific scale)
Other toxicities
Renal
Auditory
Allergic
Infection
Alopecia
Cutaneous
8 (2)
11 (4)
16 (5)
5 (1)
10 (2)
17 (5)
6 (1)
11 (6)
< 1 (< 1)
< 1 (< 1)
3 (< 1)
3 (1)
< 1 (< 1)
A recent safety evaluation in 682 patients, who received either
oxaliplatin alone or in combination with 5-FU, indicated that, at a
mean cumulative dose of900 mg m-2, 12% ofpatients experienced
grade 3 neurotoxicity, which presented as fine movement distur-
bances and moderate sensory ataxia (Figure 1) (de Gramont et al,
1997). Further evaluation has shown neuropathy grade 3/4 (Levi's
scale) to occur with oxaliplatin in 75% of patients after 12 cycles
and administration of a cumulative dose of 1560 mg m-2.
However, this cumulative sensory neuropathy is generally
reversible after discontinuation of treatment, and disappears
entirely at 6-8 months in 42% ofpatients (Table 4). The incidence
of cumulative neurotoxicity was similar for oxaliplatin mono-
therapy and the combination of oxaliplatin plus 5-FU ± FA. Little
or no ototoxicity has been observed.
SAFETY PROFILE
Overall safety
In the phase IV Extended Access Programme, patients were
treated with oxaliplatin, either as monotherapy or in combination
with 5-FU/FA. Safety data from 490 patients and 2702 cycles of
treatment have now been evaluated. Some of the patients were
heavily pretreated with oxaliplatin, being the fifth line of treat-
ment, with a median cumulative dose of 600 mgm-2 (range
70-2300 mg m-2). However, the overall safety profile of oxali-
platin in this population of patients proved to be very favourable
(Table 5) and confirmed the clinical trial results.
One phase III trial, in which the combination ofoxaliplatin plus
cyclophosphamide was compared with the combination of
cisplatin plus cyclophosphamide, has been completed in patients
with advanced ovarian cancer (Misset et al, 1997). The primary
objective ofthis multicentre trial was to evaluate the safety profile
of each treatment, and the secondary objectives were to compare
efficacy, progression-free survival and overall survival. Patients
(n = 182) were randomized to receive cisplatin 100 mg m-2 i.v. for
1 h every 3 weeks or oxaliplatin 130 mg m-2 i.v. for 2 h every
3 weeks, for six cycles of treatment. Both groups also received
cyclophosphamide 1000 mg m-2 i.v. for 2 h every 3 weeks.
An interim analysis of the safety data was performed and the
results showed that the treatment in both arms of the study was
acceptable, with over 450 cycles of treatment being administered
in each group. It was found that almost 90% ofthe planned dose of
oxaliplatin could be given. The cisplatin dose was reduced to
85.7% because of haematotoxicity. In addition, the dose of
cyclophosphamide was reduced further in this group, to 85%
compared with 90.5% in the group receiving oxaliplatin.
Haematotoxicity of grade 3/4 caused a delay in twice the
number of cisplatin treatment cycles compared with oxaliplatin
(141 compared with 70 for all grades of haematotoxicity:
P = 0.001). Gastrointestinal toxicity was also lower in the group of
patients receiving oxaliplatin, with high-grade nausea and
vomiting occurring in a significantly smallerproportion ofpatients
(oxaliplatin 7.9% compared with cisplatin 25.9%: P = 0.001).
When the levels of neurosensory toxicity were investigated, it
was found that during the early stages of the trial, low-grade toxi-
city occurred much more frequently in the group ofpatients treated
with oxaliplatin. By the end of the therapeutic programme,
however, there was a complete absence of the anticipated grade 3
toxicity in this patient group, while cumulative neurotoxicity was
Table 6 Time-related parameters
Cisplatin Oxaliplatin Significancea
(+ cyclophosphamide) (+ cyclophosphamide)
Median survival (days) 770 782 P= 0.83
(range) (12-1680+) (39-1567+) (NS)
Median time to progression (days) 432 412 P= 0.6
(range) (12-1426+) (6-1524+) (NS)
aX2
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found with cisplatin. Thus, in clinical practice, it should be
possible to treat patients with the recommended full programme of
six cycles of oxaliplatin.
Renal toxicity was shown in 9% and auditory toxicity in 4.5%
of patients treated with cisplatin, but neither toxicity was seen in
patients receiving oxaliplatin. Asthenia was also found more
frequently in patients treated with cisplatin (oxaliplatin 9.2%
compared with cisplatin 20.2%; P = 0.04).
The time-related parameters of this study are shown in Table 6.
The overall survival parameters of the two groups are very similar
at present, but the final analysis has yet to be completed.
This study has shown oxaliplatin to have a better safety profile
than cisplatin, in terms of haematological, gastrointestinal,
neurosensory and renal toxicities in the treatment of patients with
advanced ovarian cancer. No significant difference has yet been
observed between the two treatments in objective response rate,
time to progression and overall survival.
CONCLUSIONS
Oxaliplatin is a well-tolerated anticancer drug and a good candi-
date for combination therapy. The neurotoxicity that is character-
istic of the drug is acute and dose related, but is generally
reversible on discontinuation of treatment and can be managed
satisfactorily in clinical practice.
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